Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis  by Esther, Charles R. et al.
Journal of Cystic Fibrosis 9 (2010) 117–123
www.elsevier.com/locate/jcfOriginal article
Chronic Mycobacterium abscessus infection and lung function decline in
cystic fibrosis
Charles R. Esther Jr. ⁎, Denise A. Esserman, Peter Gilligan, Alan Kerr, Peadar G. Noone
Statistics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Clinical Microbiology–Immunology Laboratories, University of North Carolina Hospitals, Chapel Hill, NC 27599, USA
Pulmonology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Received 12 October 2009; received in revised form 4 December 2009; accepted 7 December 2009
Available online 13 January 2010Abstract
Background: Although nontuberculous mycobacteria (NTM) are recognized pathogens in cystic fibrosis (CF), associations with clinical outcomes
remain unclear.
Methods: Microbiological data was obtained from 1216 CF patients over 8 years (481±55 patients/year). Relationships to clinical outcomes were
examined in the subset (n=271, 203±23 patients/year) with longitudinal data.
Results: Five hundred thirty-six of 4862 (11%) acid-fast bacilli (AFB) cultures grew NTM, with Mycobacterium abscessus (n=298, 55.6%) and
Mycobacterium avium complex (n=190, 35.4%) most common. Associated bacterial cultures grew Stenotrophomonas or Aspergillus species
more often when NTM were isolated (18.2% vs. 8.4% and 13.9% vs. 7.2%, respectively, pb0.01). After controlling for confounders, patients with
chronic M. abscessus infection had greater rates of lung function decline than those with no NTM infection (−2.52 vs. −1.64% predicted FEV1/
year, pb0.05).
Conclusions: NTM infection is common in CF and associated with particular pathogens. Chronic M. abscessus infection is associated with
increased lung function decline.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Nontuberculous mycobacteria1. Introduction
Nontuberculous mycobacteria (NTM) are ubiquitous envi-
ronmental mycobacteria that have the potential to cause res-
piratory disease [1], particularly in hosts with compromised
lung defenses such as patients with cystic fibrosis (CF) [2,3].
Recovery of NTM from CF respiratory secretions is relatively
common, with an overall prevalence of 13% reported in a large
prospective study [4]. More recent studies have suggested that
the NTM prevalence in CF may be increasing [5,6], though it
is not clear if this represents increasing rates of infection or
improved surveillance [7].⁎ Corresponding author. Pediatric Pulmonology, CB#7217, University of
North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Tel.: +1 919 966
1055; fax: +1 919 966 6179.
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doi:10.1016/j.jcf.2009.12.001While the potential for NTM to cause respiratory disease is
well established, the clinical impact of chronic NTM infection
in CF is not well defined [2]. Although associations between
NTM infection and clinical deterioration in CF have been re-
ported [8–10], the largest prospective study of NTM infection
in CF to date did not demonstrate a relationship between NTM
infection and worsening lung function [11]. Establishing a
relationship between chronic NTM infection and clinical se-
verity in CF is complicated by the many factors that influence
respiratory deterioration in CF, as well as the overlap between
features of CF and NTM respiratory disease [2].
We hypothesized that examination of a large database over a
long interval would reveal relationships between chronic NTM
infection and clinical disease in CF. Therefore, we retrospec-
tively examined a microbiological database of all culture results,
including acid-fast bacterial (AFB) cultures for NTM, from 1216
patients with CF at a single university CF center from 2000d by Elsevier B.V. All rights reserved.
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isolation and clinical outcomes through evaluation of a subset
of 271 patients with at least 3 years of available longitudinal
clinical data.
2. Methods
2.1. Microbiological data
Cultures for acid-fast bacilli, bacterial, and fungal pathogens
were performed using standardized methods [12]. Culture re-
sults were obtained from a database maintained by the Clinical
Microbiology–Immunology Laboratories at the University of
North Carolina Hospitals and included results from 13,033
bacterial and fungal cultures and 4862 acid-fast bacterial (AFB)
cultures performed on 1216 patients with CF from 2000 to
2007. On average, the database included 608±299 AFB culture
results and 481±55 individual patients each year. In the last
year of the study (2007), introduction of hsp65 sequence anal-
ysis revealed that a subset of mycobacterial species previously
identified as Mycobacterium abscessus could not be distin-
guished from another member of the M. abscessus group, My-
cobacterium massiliense. Prior to this year, NTM speciation
was based on standard biochemical methods [12,13]. For sim-
plicity and consistency with previous publications, both M.
massiliense and M. abscessus are referred to as M. abscessus
within this manuscript.
2.2. Clinical data
Clinical data was abstracted from the PortCF database for
adult and pediatric CF programs at the University of North
Carolina. Demographic data were recorded for each calendar
year, with age in each calendar year defined as age on the
subject's day of birth. In the clinical correlation analyses, only
patients with at least three AFB cultures in the microbiology
database and at least three calendar years of lung function data
at age 6 years or older were included. For this subset, data on
lung function, body mass index (BMI), diagnosis of CF related
diabetes mellitus, and diagnosis of allergic bronchopulmonary
aspergillosis (ABPA), and care episodes (intravenous antibiotic
treatment) were abstracted from Port CF. For clinical para-
meters in which multiple values were obtained throughout the
calendar year (e.g., percent predicted FEV1, and body mass
index), the maximum value was recorded for each year. Within
this cohort, chronic NTM infection was defined as three or more
cultures positive for NTM over three or more quarterly visits.
This study was approved by the Office of Human Research
Ethics at the University of North Carolina at Chapel Hill.
2.3. Statistical analysis
Descriptive statistics were calculated for year of first entry
into the study for groups classified by NTM infection status.
These are presented as means and standard deviations (SD)
for continuous variables and proportions for categorical vari-
ables. Characteristics included gender; pancreatic insufficiency(≥2 years pancreatic enzyme use); chronic Pseudomonas
infection (≥2 years with one or more cultures positive for
Pseudomonas aeruginosa); nutritional failure (average BMIb
19 [adults] or percent predicted BMIb10% [children]); ABPA
(diagnosed on at least one occasion); and CF related diabetes
(diagnosed on at least one occasion) were obtained from the
data abstracted from PortCF.
Comparisons were made for continuous variables using the
non-parametric Mann–Whitney test (bivariate) or the Krusal–
Wallis test with Dunn's post test (multivariate). The chi-squared
test of association (or Fisher's exact test, where necessary)
was utilized for categorical comparisons; post hoc bivariate
comparisons were conducted if there were more than 2 levels
for each variable.
To examine the relationship between chronic NTM infection
and changes in lung function over time, linear mixed models
with a random intercept and slope were fit to determine the
effect of NTM infection status on percent predicted FEV1 over
time (year of age) using maximum likelihood estimation. Each
patient contributed a minimum of 3 and a maximum of 8 (1 per
year) data points. The primary covariate of interest was the
interaction between time (year of age) and infection status. In
addition to age, infection status, and their interaction, models
were adjusted for confounders established a priori as defined
above: gender; pancreatic insufficiency, chronic Pseudomonas
infection, nutritional failure, ABPA, and CF related diabetes.
Statistical significance was established at 0.05. All analyses
were conducted in GraphPad Prism (La Jolla, CA) or SAS
version 9.2 (SAS, Cary, NC).
3. Results
3.1. Prevalence of NTM and its relation to other pathogens
Of the 1216 CF patients included in the database, 829 (68%)
had one or more AFB cultures obtained over the course of
the study for a total of 4862 AFB cultures (average 5.9 AFB
cultures per patient). NTM were isolated from 536 (11.0%) of
these AFB cultures. M. abscessus was the most commonly
NTM species cultured, representing 298 (55.6%) of the isolates;
Mycobacterium avium complex was second with 190 (35.4%)
isolates (Fig. 1A). Other mycobacterial species, including
M. gordonae and M. kansasii, were identified at much lower
frequencies (b5% for each).
The 536 NTM isolates were obtained from 166 individual
patients (13.7% of the entire cohort, 20.0% of the cohort with at
least one AFB culture). Among these NTM positive patients, 98
(59.0%) patients had at least one positive culture for M. avium,
with an average of 1.9±1.9 M. avium isolates per patient;
whereas 68 (41.0%) patients had at least one positive culture for
M. abscessus with an average of 4.9±7.0 M. abscessus isolates
per patient. M. abscessus represented the majority (55.6%) of
NTM positive isolates but a smaller proportion (41.0%) of
the NTM positive patients, reflecting the greater number of
M. abscessus isolates per patient.
The relationships between NTM and other CF pathogens
were determined by examining the 3789 instances in which an
Fig. 1. Prevalence of NTM species and associated pathogens. A) Relative
distribution of NTM species (n=536). M. abs=M. abscessus, M. avi=M. avium
complex, and M. gor=M. gordonae. Others included all other NTM,
predominantly unidentified species (n=33) but small numbers of M. fortuitum
(n=3), M. B) Frequency of culture positivity for various CF pathogens in
bacterial/fungal cultures associated with NTM+ or NTM− AFB cultures. P.
aer=P. aeruginosa, S. aur=Staphylococcus aureus, S. mal=S. maltophilia,and
A. xyl=Achromobacter xylosoxidans. A. fum=Aspergillus fumigatus. *pb0.05
NTM+ vs. NTM− by Chi-squared analysis.
Fig. 2. Age distribution and annual prevalence of NTM infection. Prevalence
was calculated form records of 1216 CF patients with at least one micro-
biological culture obtained from a single university CF center from 2000 to
2007. A) For each year of age, the percentage of patients with at least one AFB
culture attempt (squares) was determined, as was the percentage of patients with
at least one culture positive for NTM among all patients (triangles) and AFB
screened patients (circles). Older patients were more likely to have both AFB
culture attempts and NTM isolated from AFB cultures. B) For each calendar
year of the study, the percentage of patients with at least one AFB culture
attempt (squares) and at least culture positive for NTM among all patients
(triangles) and AFB screened patients (circles) was determined. Among all
patients, the percentage of AFB cultures and NTM positive cultures increased
over time, although the percentage of NTM positive cultures among AFB
screened patients remained relatively constant.
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fungi were obtained from the same patient on the same date.
When NTM were recovered from AFB cultures, the associated
bacterial/fungal cultures had a higher prevalence of Stenotro-
phomonas maltophilia (18.2% vs. 8.4%, pb0.01) and A.
fumigatus (13.9% vs. 7.2%, pb0.01) than when AFB cultures
were negative for NTM (Fig. 1B). Conversely, P. aeruginosa
was less commonly associated with NTM positive cultures
(50.8% NTM positive vs. 57.9% NTM negative, pb0.01).
Because previous studies suggested that NTM infection was
more common in older individuals with CF [4], we examined
the relationship between NTM infection and age. In the very
young (b5 years of age), the percentage of patients with NTM
positive cultures was low (mean 1.3±0.4%). Prevalence slowly
increased with age until age 14, then remained fairly constant
(mean 11.0±3.3%, range 5.7–20.6%) (Fig. 2A). Although we
did not observe a marked increase in NTM prevalence with age,
overall prevalence was modestly increased in the older CF
population (13.2±3.8% ages 40+) compared to adolescents and
younger adults (9.9±2.6% ages 14–39, pb0.05). Although
these findings are consistent with previous reports [4,5,14],
interpretation of the data is limited by the fact that AFB cultures
were primarily obtained from bronchoalveolar lavage fluid inthe young (≤5 years old) and sputum from older individuals,
which complicates comparison of prevalence estimates across
ages.
To determine whether the prevalence of NTM changed over
time, we assessed the prevalence of patients with NTM positive
cultures in each calendar year. The number of patients with at
least one NTM positive culture increased from 2000 to 2007,
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0.7±0.2% annual increase of the total cohort (pb0.01, Fig. 2B).
However, the number of patients with at least one AFB culture
attempt each year also increased significantly over time (4.9±
1.0% annual increase, pb0.01). Interestingly, the percentage
of AFB screened patients who were NTM positive each year
remained relatively unchanged throughout the study (range
11.5–16%, Fig. 2B).3.2. Clinical correlates of chronic NTM infection
We next examined relationships between NTM infection
and clinical parameters, using a subset of patients who had
longitudinal clinical data available and were screened for AFB
as defined in Section 2. A total of 271 patients were included
(mean 203±23 patients per year, 6.0±1.9 years of data per
patient). From this group, 95 patients (35% of entire cohort) had
at least one NTM positive culture over the time frame of the
study, with a mean annual prevalence of 10.8±1.6%. Of these
95 patients, 52 patients (55%) had at least one positive culture
for M. avium, and 38 patients (40%) had at least one positive
culture for M. abscessus. The percentage of NTM positive
patients per year (both of the total group and of those with AFB
screening) was similar to those measured in the total cohort
(Fig. 3A, compare to Fig. 2A), although the overall prevalence
of NTM was higher.
To determine if NTM infection was more common in
patients with more severe clinical disease, we examined dif-Fig. 3. Prevalence of NTM in patients with longitudinal clinical data. The subset
of CF patients with at least three AFB culture attempts and at least 3 years of
lung function data was examined (n=271). Within this group, the percentage of
patients with at least one AFB culture attempt (squares) and at least one positive
culture for NTM among all patients (triangles) and those patients with least one
AFB culture attempt (circles) was determined. As with the larger group, the
percentage of patients with AFB cultures and NTM positive cultures increased
over time, although the percentage of patients with AFB culture attempts that
were NTM positive was relatively constant.ferences in specific clinical parameters between patients with
chronic NTM infection (three or more AFB cultures positive for
NTM, n=38) and those with no positive NTM isolates despite
at least three AFB cultures (n=178). All of the patients with
chronic NTM infection meet the recently revised ATS micro-
biological criteria for NTM infection [15]. The demographic
characteristics of the groups were similar, although the chronic
NTM infection group included fewer females (Table 1). Rates
of ABPA and CF related diabetes were similar between groups,
although an increased rate of CF related diabetes in the chronic
NTM infection group (7/23) compared to the no NTM infection
group (9/87, p=0.04) was observed in the pediatric group (age
18 or younger). Average lung function values (percent predicted
FEV1) at study entry were not different between groups.
Because the clinical impact of NTM infection may be worse
with rapidly growing mycobacteria [8], we separately examined
the subset of subjects with chronic M. abscessus infection
(n=23). The demographic features of this group were similar to
those of the no NTM infection group except for higher rates of
nutritional failure (Table 1). We observed that subjects with at
least one positive culture for M. abscessus had a higher rate of
chronic infection (23 with chronic infection among 38 with at
least oneM. abscessus positive culture, 61%) than those with at
least one positive M. avium culture (10 with chronic infection
among 53 with at least one positive M. avium culture, 19.2%,
pb0.001). Of note, five patients met the definition of chronic
NTM infection with more than one NTM species and did not
meet the criteria for either chronic M. abscessus or chronic
M. avium infection.
3.3. Lung function decline in chronic NTM infection
To determine the relationship between chronic NTM
infection and longitudinal changes in lung function, weTable 1
Characteristics of the longitudinal study cohort (n=271).
Characteristic ⁎ No NTM
infection
Chronic NTM
infection
Chronic M. abscessus
infection
n=178 n=38 n=23
Age, years 18.8±11.5 17.1±11.5 16.4±10.4
Gender, female 93 (52.2) 11 (28.9) ⁎⁎ 8 (34.8)
FEV1, % predicted 76.7±27.6 79.4±24.1 79.4±21.4
Pancreatic
insufficient (%)
170 (95.5) 36 (94.7) 21 (91.3)
Chronic
Pseudomonas (%)
154 (86.5) 32 (84.2) 18 (78.3)
Nutritional failure
(%)
40 (22.5) 13 (24.2) 10 (43.5) ⁎⁎
ABPA (%) 18 (10.7) 4 (10.5) 3 (13.6)
CFRD (%) 43 (24.2) 12 (31.5) 7 (30.4)
Years in study 5.9±2.0 6.2±1.9 6.2±2.0
NTM, nontuberculous mycobacteria; ABPA, allergic bronchopulmonary
aspergillosis; CFRD, cystic fibrosis related diabetes.
⁎ Characteristics were defined as described in the Section 2. Note that ABPA
(%) included data from only 168 NoNTM infection and 21 chronicM. abscessus
infection patients.
⁎⁎ pb0.05 vs. no NTM infection by Chi-squared analysis.
Fig. 4. Model of changes in FEV1 % predicted over time in chronic NTM
infection, adjusted for confounders. Using the data from Table 2, a model of
lung function decline over time was generated for groups of patients with no
NTM infection (solid line) and chronicM. abscessus infection (dashed line) after
adjustment for potential confounders. This model demonstrates the worsening
decline in lung function over time in the chronic M. abscessus infection group.
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FEV1, age, and several potential confounders including gender,
chronic Pseudomonas infection, nutritional failure, CF related
diabetes, and ABPA. As expected, we observed an overall
relationship between lung function and year of age, reflecting
an annual decline of −1.64% predicted FEV1 per year (Table 2).
The subjects with chronic M. abscessus infection had an excess
decline of −0.78% predicted FEV1 per year over the no NTM
infection group, for a total annual decline of -2.42%/year
(p=0.02 vs. no NTM infection, Table 2, Fig. 4). Interestingly,
the rate of lung function decline in the group of patients who
had chronic NTM infection but not chronic M. abscessus
infection (excess decline −0.57%/year, total decline, total de-
cline −2.21%/year) was intermediate between, but not statis-
tically different from, the rate of decline in the no NTM
infection and chronic M. abscessus infection groups. Overall,
the group with chronic NTM infection (any species) had a
higher rate of annual decline in percent predicted FEV1
(−2.33%/yr, pb0.01 vs. no NTM infection, data not shown).
Interestingly, patients with chronic M. abscessus infection
received more intravenous antibiotic treatment (31.3±37.0 days
treatment/year) than patients with no NTM infection (17.6±
9.4 days treatment/year, pb0.01). However, the impact of
treatment directed against NTM was difficult to assess, since
the clinical database does not distinguish between treatments
directed against NTM vs. other CF pathogens.4. Discussion
This study provides the strongest evidence to date that
chronic NTM infection, particularly chronic infection with
M. abscessus, is associated with worsening lung function over
time in patients with CF. Although consistent with the view ofTable 2
Impact of chronic NTM infection on lung function changes over time, adjusted
for confounders.
Characteristic Coefficient 95% CI p value
Age, years −1.64 −1.87 to −1.41 b.0001
Chronic NTM infection∗age, years ⁎ 0.0284
Age∗chronic M. abs infection −0.78 −1.43 to −0.12
Age∗chronic NTM infection, no
M. abs −0.57 −1.31 to 0.17
Infection status ⁎⁎ 0.0372
Chronic M. abs infection 9.72 −1.14 to 20.58
Chronic NTM infection, no M. abs 13.64 0.73 to 26.55
Gender, female 5.59 0.42 to 10.75 0.0340
Pancreatic insufficient −10.82 −28.33 to 6.68 0.2251
Chronic Pseudomonas −9.69 −16.92 to −2.46 0.0087
Nutritional failure −13.55 −19.79 to −7.31 b.0001
ABPA −3.73 −11.65 to 4.20 0.3561
CFRD −10.54 −17.22 to −3.86 0.0020
NTM, nontuberculous mycobacteria; M. abs, M. abscessus; ABPA, allergic
bronchopulmonary aspergillosis; CFRD, cystic fibrosis related diabetes.
Characteristics are defined as in Table 1.
⁎ Reference group=age∗no infection.
⁎⁎ Reference group=no infection.NTM as respiratory pathogens in CF, the relationships between
chronic NTM respiratory infection and clinical disease in CF
have been difficult to establish [2,3]. One of the largest pro-
spective studies of NTM infection to date [11] failed to uncover
a statistically significant effect of chronic NTM infection on
lung function decline. Interestingly, the authors of that study
determined that observed differences in FEV1 might become
statistically significant if follow-up were extended to 6.4 years,
a time frame similar to that of our study (mean 6.0±1.9 years of
data per patient). Although substantial differences in method-
ology preclude a direct comparison between studies, the longer
time frame available for our retrospective analysis may explain
our greater ability to detect the impact of chronic NTM infection
on lung function decline even after controlling for potential
confounders.
Based on the known pathogenicity of NTM [1,2,15], we
suspect that chronic NTM infection directly contributes to
worsening lung function in patients with CF. Direct causation
would also be consistent with the fact that excess lung function
decline was most clearly observed in those patients infected
withM. abscessus, generally considered to be a virulent species
of NTM [16–18]. However, the data demonstrate an associa-
tion, and we cannot exclude the possibility that NTM infection
is a marker of worsening CF lung disease rather than a causative
factor. Nevertheless, the fact that lung function (% predicted
FEV1) was similar in the no NTM infection and chronic NTM
infection groups at the start of the study suggests that NTM
infection was not limited to patients with more severe pre-
existing lung disease. We did not observe a relationship
between chronic NTM infection and pancreatic sufficiency, a
marker of “mild” CF mutations [19]. Furthermore, while we
observed some relationships between chronic NTM infection
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and CF related diabetes, the association between infection and
lung function decline remained significant even after control-
ling for these potential confounders. Thus, a causative rela-
tionship between NTM infection and lung function decline
seems likely, although prospective studies with more universal
screening will be necessary to address this issue. Interestingly,
the decline in lung function occurred despite the fact that
patients with chronic M. abscessus infection received greater
treatment with intravenous antibiotics. Based on our clinical
experience with NTM infected CF patients at our institution, we
suspect that some of this treatment reflects antibiotics directed
against NTM. However, assessing the impact of this treat-
ment on lung function and other clinical parameters will require
further, prospective study.
Although our study population was limited to a single center,
our findings are similar to previous studies of NTM infection
in CF. For example, overall prevalence of NTM infection in
our CF population (mean annual prevalence 10.8%) and its
relationship to age are similar to those previously described
[4,5]. In addition, the association of NTM with other known
CF pathogens including Stenotrophomonas and Aspergillus
species is consistent with previous literature, as was the modest
but statistically significant negative association between NTM
and P. aeruginosa [4,5]. While this negative relationship could
reflect an interaction between NTM and Pseudomonas infection
within the airway, we cannot rule out the possibility that this
association results from technical factors; e.g., the well rec-
ognized propensity of Pseudomonas species to overgrow NTM
in a small fraction of AFB cultures despite decontamination
procedures [7,20]. In our population, M. abscessus represented
a higher fraction of NTM isolates than typically reported [4,9],
although higher rates of infection with this organism have been
observed [5,21]. We suspect that this greater number of M.
abscessus positive cultures reflects its propensity for causing
chronic infection relative to other NTM species [8,10], resulting
in more positive cultures per patient over the course of this
longitudinal study. It is also possible that this rapidly growing
NTM may have a higher recovery rate in the presence of
overgrowth with Pseudomonas species.
The relatively long time frame of our study allowed us to
determine whether the prevalence of NTM infection was
changing over time in our CF population. While we observed
increasing prevalence of documented NTM infection over the
8 years of this study, much of this increase could be accounted
for by higher rates of AFB screening, and the percentage NTM
positive patients among AFB screened population was relatively
constant. Our data suggest that increased prevalence of NTM
could reflect improved surveillance, and universal screening may
be needed to effectively identify all CF patients with NTM
infection. However, further investigation is needed to determine
the clinical benefit of universal screening.
In summary, our study demonstrates that NTM are common
respiratory pathogens in CF, and that chronic NTM infection is
associated with clinical deterioration as measured by an in-
creased rate of decline in FEV1. These findings further highlight
the need for both effective NTM screening and further researchon effective treatment modalities for those with chronic NTM
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